Don’t include trimethoprimBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39542.480324.3A (Published 10 April 2008) Cite this as: BMJ 2008;336:787
- Robin A Howe, head, Welsh Antimicrobial Resistance Programme, National Public Health Service for Wales
- 1Cardiff Microbiology (Velindre NHS Trust), University Hospital of Wales, Cardiff CF14 4XW
The Medicines and Healthcare Products Regulatory Agency (MHRA) moves to recommend, for the first time, that a systemic antibiotic (trimethoprim) should have its licence reclassified from prescription only medicine (POM) to pharmacy (P) availability.1 For systemic antibiotics particular concerns exist that do not apply to other medicines.
The use of antibiotics may have an adverse effect not only on the specific patient but also on the public health of the community. Quantifying the relation between antibiotic exposure and resistance …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial